Ph: not bad at all

被引：2

作者：

Guilhot, Francois ^{[1
]}

机构：

[1] CHU Poitiers, Poitiers, France

来源：

BLOOD | 2011年 / 117卷 / 25期

关键词：

CHRONIC MYELOID-LEUKEMIA; POOR-PROGNOSIS; DELETIONS; TRANSLOCATIONS;

D O I：

10.1182/blood-2011-04-346650

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：6741 / 6742

页数：2

共 9 条

[1] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[2] Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With Imatinib Mesylate: GIMEMA CML Working Party Analysis [J].

Castagnetti, Fausto ;

Testoni, Nicoletta ;

Luatti, Simona ;

Marzocchi, Giulia ;

Mancini, Marco ;

Kerim, Simonetta ;

Giugliano, Emilia ;

Albano, Francesco ;

Cuneo, Antonio ;

Abruzzese, Elisabetta ;

Martino, Bruno ;

Palandri, Francesca ;

Amabile, Marilina ;

Iacobucci, Ilaria ;

Alimena, Giuliana ;

Pane, Fabrizio ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Baccarani, Michele ;

Rosti, Gianantonio .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2748-2754

[3] Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions [J].

Huntly, BJP ;

Guilhot, F ;

Reid, AG ;

Vassiliou, G ;

Hennig, E ;

Franke, C ;

Byrne, J ;

Brizard, A ;

Niederwieser, D ;

Freeman-Edward, J ;

Cuthbert, G ;

Bown, N ;

Clark, RE ;

Nacheva, EP ;

Green, AR ;

Deininger, MWN .

BLOOD, 2003, 102 (06) :2205-2212

[4] Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [J].

Huntly, BJP ;

Reid, AG ;

Bench, AJ ;

Campbell, LJ ;

Telford, N ;

Shepherd, P ;

Szer, J ;

Prince, HM ;

Turner, P ;

Grace, C ;

Nacheva, EP ;

Green, AR .

BLOOD, 2001, 98 (06) :1732-1738

[5]

HURET JL, 1990, HUM GENET, V85, P565

[6] Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis [J].

Marzocchi, Giulia ;

Castagnetti, Fausto ;

Luatti, Simona ;

Baldazzi, Carmen ;

Stacchini, Monica ;

Gugliotta, Gabriele ;

Amabile, Marilina ;

Specchia, Giorgina ;

Sessarego, Mario ;

Giussani, Ursula ;

Valori, Laura ;

Discepoli, Giancarlo ;

Montaldi, Anna ;

Santoro, Alessandra ;

Bonaldi, Laura ;

Giudici, Giovanni ;

Cianciulli, Anna Maria ;

Giacobbi, Francesca ;

Palandri, Francesca ;

Pane, Fabrizio ;

Saglio, Giuseppe ;

Martinelli, Giovanni ;

Baccarani, Michele ;

Rosti, Gianantonio ;

Testoni, Nicoletta .

BLOOD, 2011, 117 (25) :6793-6800

[7] Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia [J].

Reid, AG ;

Huntly, BJP ;

Grace, C ;

Green, AR ;

Nacheva, EP .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (03) :419-427

[8] Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia [J].

Sinclair, PB ;

Nacheva, EP ;

Leversha, M ;

Telford, N ;

Chang, J ;

Reid, A ;

Bench, A ;

Champion, K ;

Huntly, B ;

Green, AR .

BLOOD, 2000, 95 (03) :738-744

[9] Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors [J].

Stagno, Fabio ;

Vigneri, Paolo ;

Del Fabro, Vittorio ;

Stella, Stefania ;

Cupri, Alessandra ;

Massimino, Michele ;

Consoli, Carla ;

Tambe, Loredana ;

Consoli, Maria Letizia ;

Antolino, Agostino ;

Di Raimondo, Francesco .

ACTA ONCOLOGICA, 2010, 49 (04) :506-508

← 1 →